Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Michael King, Chief Executive ...

For decades, lab-made antibodies have been used to support patients fighting specific diseases. These treatments have become ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States ...